Multiple sclerosis, a treatable disease by Doshi, A & Chataway, J
Figure 1. Trajectory of MS
Figure1. Relapse onset MS leads to the progressive accumulation of disability after 10-15 years with fewer
relapses and MRI T2 lesions or gadolinium-enhancing lesions.
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Figure 2. Armamentarium of disease-modifying therapies (DMTs) 2016
Approved DMTs in 2016;  β-interferon-1a(Avonex), β-interferon-1b(betaferon), Glatiramer Acetate (Copaxone), 
Mitoxantrone (Novantrone)*, β-interferon-1a(Rebif), Natalizumab (Tysabri), Teriflunomide (Aubagio), 
Alemtuzumab (Lemtrada), Fingolimod (Gilenya), Dimethyl fumarate (Tecfidera),Interferon beta 1b (Extavia), β-
interferon-1a (Plegridy).
This is a line graph of MS disease-modifying therapies (DMTs) which have European Medicines Agency (EMA) or
Food and Drug Administration (FDA) approval. The vertical axis is the number of approved disease modifying
therapies. The horizontal axis is year of approval. *Mitoxantrone (Novantrone) has FDA approval only.
Treatment Mode and frequency Side effects Indication* Notes
Interferon beta 1a
(Avonex)
Intramuscular injection.
30 micrograms. once
weekly.
>1:100; Flu-like,
injection site
reactions, headache,
lymphopaenia,
insomnia, diarrhoea,
nausea and vomiting,
depression, hair loss,
liver function
derangement, thyroid
disease.
*Caution re:
neutralising antibodies
in up to 46% of
patients. Monitor
antibody titres.
First-line: active
RRMS with ≥2 
relapses, or 1
relapse and new
MRI lesions as
per Mcdonald
2010 criteria
in≤2 years. 
EDSS<6.5 (able
to walk 20m)
CIS and high risk
of developing
MS with MRI T2
lesions.
*SPMS with ≥2 
relapses in ≤2 
years and EDSS
progression ≤2 
points over 2
years.
Fridge storage.
Caution if
depression/suicidal
ideation.
Pegylated Interferon
beta 1a (Plegridy)
Subcutaneous injection.
Start with a dose of 63
micrograms on day 1,
followed by 94
micrograms on day 15,
then 125 micrograms
on day 29 and once
every 2 weeks
thereafter.
Fridge storage.
Keep out of sunlight.
Interferon beta 1a
(Rebif)
Subcutaneous injection.
Start at 22 micrograms
three times weekly and
escalate over 4 weeks
to 44micrograms three
times weekly.
Fridge storage
*Interferon beta 1b
(Betaferon)
Subcutaneous injection.
Alternate days. Escalate
to 250 micrograms over
3-6 weeks.
*Interferon beta 1b
(Extavia)
Glatiramer acetate
(Copaxone)
Subcutaneous injection.
20 milligrams once
daily. OR, 40 milligrams
three times per week.
>1:100; injection site
reactions including
lipoatrophy, headache,
depression, anxiety,
nausea. Also IPIR with
flushing, palpitations,
dyspnoea, chest pain
lasting 15-30 minutes.
First-line: active
RRMS with ≥2 
relapses, or 1
relapse and new
MRI lesions as
per Mcdonald
2010 criteria in
≤2 years. Able to 
walk more than
100m without
aids.
CIS and high risk
of developing
MS with MRI T2
lesions.
SPMS with ≥2 
relapses in ≤2 
years and EDSS
progression ≤2 
points over 2
years.
If IPIR lasts longer than
30 minutes then
patients should seek
urgent medical
attention.
Teriflunamide
(Aubagio)
Oral. 7 or 14 milligrams
once daily.
>1:100; liver function
derangement,
diarrhoea, nausea, hair
thinning and loss.
First-line: active
RRMS with ≥2 
relapses, or 1
relapse and new
MRI lesions in ≤2 
years.
Dimethyl fumarate
(Tecfidera)
Oral. Initially 120
milligrams twice daily,
and then increase after
7 days to 240mg twice
daily.
>1:100; flushing,
gastrointestinal upset,
lymphopaenia, rash,
ketonuria, proteinuria,
liver function
derangement. Very
First-line: active
RRMS with ≥2 
relapses, or 1
relapse and new
MRI lesions in ≤2 
years.
Taking oral doses with
food may reduce the
incidence of flushing
and gastrointestinal
effects.
rare cases of PML
reported
.
Fingolimod (Gilenya) Oral. 500 micrograms
once daily.
>1:100; cough,
headache, back pain,
diarrhoea, infections,
liver function
derangement,
lymphopaenia.
<1:100; macular
oedema. Very rare
cases of PML reported.
Second-line:
Highly active
RRMS only with
same/increased
relapses despite
treatment with
beta
interferon(pre-
NICE approval)
or glatiramer
acetate (2014
post-NICE
approval) over
the last year.
RRMS on
Natalizumab at
high risk of
PML.(2014 post-
NICE approval)
First-line:
Across UK, ABN
guidance
suggests
fingolimod can
be used if highly
active RRMS.
Note: Bradycardia and
atrioventricular
conduction slowing
can occur whilst taking
the first dose of
fingolimod, therefore
the first dose is taken
under medical
supervision and
cardiac monitoring for
6 hours.
Natalizumab (Tysabri) Intravenous infusion.
300 milligrams once
every 4 weeks.
>1:100; headache,
dizziness, pruritic rash,
infections.
Clear risk gradient of
PML.
First-line:
RES RRMS with
≥2 relapses ≤ 1 
year + no
previous DMT
and either a) ≥1 
gadolinium
enhancing MRI
lesion or b) ≥9 
T2-hyperintense
MRI brain
lesions if MRI
available.
Second-line:
RES RRMS with
≥1 relapses ≤ 1 
year + previous
beta interferon
not meeting
stopping criteria
and either a) ≥1 
gadolinium
enhancing MRI
lesion or b) ≥9 
T2-hyperintense
MRI brain
lesions if MRI
available.
.
Alemtuzumab
(Lemtrada)
Intravenous infusion.
Initially: 12 milligrams
daily for 5 consecutive
days to a total dose of
>1:100; acute cytokine
release syndrome
(headaches, rash,
fever, nausea,
First-line: active
RRMS with ≥2 
relapses in ≤2 
years, or 1
Usually due to side
effect profile,
alemtuzumab is
usually restricted to
60 milligrams. Second
course: 12 months post
initial dose. 12
milligrams daily for 3
consecutive days to a
total dose of 36
milligrams.
diarrhoea,
hypotension),
infections including
herpes virus,
endocrinopathy.
relapse and new
MRI lesions.
Second-line:
Highly active
RRMS on DMT
and relapse
within the last
year and new
MRI lesions..
those with more active
RRMS.
Pre-medications: oral
or intravenous
corticosteroid, oral
antihistamine, and
analgesic to prevent
cytokine release
syndrome. Oral
prophylaxis with
aciclovir for herpes
infection and
continued for one
month.
Table 3. UK-licensed disease-modifying treatments (DMTs) for Relapsing Remitting MS
Glossary: RRMS (Relapsing Remitting Multiple Sclerosis), EDSS (Expanded Disability Status Scale), CIS (Clinically
Isolated Syndrome), SPMS ( Secondary Progressive Multiple Sclerosis), IPIR (immediate post-injection
reaction), RES (Rapidly evolving severe), PML (Progressive Multifocal Leucoencephalopathy), ABN(Association
of British Neurologists).
Comment: NHS England has taken on commisioning of the drugs since 2013 and advices that patients must be
under the care of a designated MS centre which is registered to take part in the national risk sharing scheme
involving the three beta interferon products and glatiramer acetate. The Association of British Neurologists
(ABN) advices an annual review whilst on DMTs that will need to be conducted by the MS specialist
neurologist who is also best placed to determine whether MRI scanning is required.
Sources:
1. Scolding N, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-
modifying treatments in multiple sclerosis. Practical Neurology 2015;15(4):273-279.
2. Multiple Sclerosis Trust. Disease Modifying Drugs. Multiple Sclerosis Trust Publication ID 90. November
2015.
3. National Institute for Clinical Excellence (NICE) Clinical Guidelines CG186. Multiple sclerosis in adults:
management. October 2014.
4. National Health Service (NHS) England. Clinical commissioning policy: disease modifying therapies for
patients with multiple sclerosis (MS) May 2014 NHS England/ D04/P/b
5. https://www.medicinescomplete.com/mc/martindale
Drug Interventional Multi-disciplinary input
Fatigue Amantadine Occupational therapy
and physiotherapy:
fatigue management
assessment and exercise
programme
Cognition/ low mood Depression: citalopram,
duloxetine
Neuropsychology
service, cognitive
behavioural therapy,
occupational therapy
Spasticity Baclofen, gabapentin,
tizanidine, clonazepam,
dantrolene
Intrathecal baclofen,
botulinum toxin
Physiotherapy
Bladder Frequency/urgency:
Oxybutynin, solifenacin,
tolterodine, mirabegron
Nocturia: Desmopressin/
DDAVP spray
Residual bladder
volume > 100mls:
intermittent self-
catheterisation or
permanent catheter;
intravesicular botulinum
toxin,
Uro-neurology
Sexual dysfunction Sildenafil, tadalafil,
alprostadil, yohimbine
Uro-neurology
Constipation Fibre/fluid, bulking
agents, osmotic stimulant
laxatives, suppositories,
transanal irrigation
Faecal incontinence Codeine, loperamide Biofeedback, neuro-
gastroenterology
Pain Amitriptyline, pregabalin,
gabapentin, lamotrigine
Ataxia/Tremor Propranolol, clonazepam,
levetiracetam, isoniazid
(with pyridoxine),
carbamazepine,
ondansetron
Botulinum toxin,
thalamotomy
Physiotherapy ,
occupational therapy,
audiovestibular therapy
Oscillopsia Gabapentin, memantine,
levetiracetam,
clonazepam, baclofen
Neuro-ophthalmology
Table 4. Suggested symptomatic treatments in MS
